Your browser doesn't support javascript.
loading
In vitro and in vivo activity of cefiderocol against Achromobacter spp. and Burkholderia cepacia complex, including carbapenem-non-susceptible isolates.
Takemura, Miki; Nakamura, Rio; Ota, Merime; Nakai, Ryuichiro; Sahm, Daniel F; Hackel, Meredith A; Yamano, Yoshinori.
Afiliação
  • Takemura M; Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
  • Nakamura R; Department of Biofunctional Evaluation ΙI, Shionogi TechnoAdvance Research & Co., Ltd., Osaka, Japan.
  • Ota M; Department of Biofunctional Evaluation ΙI, Shionogi TechnoAdvance Research & Co., Ltd., Osaka, Japan.
  • Nakai R; Department of Biofunctional Evaluation ΙI, Shionogi TechnoAdvance Research & Co., Ltd., Osaka, Japan.
  • Sahm DF; International Health Management Associates, Schaumburg, Illinois, USA.
  • Hackel MA; International Health Management Associates, Schaumburg, Illinois, USA.
  • Yamano Y; Laboratory for Drug Discovery and Disease Research, Shionogi & Co., Ltd., Osaka, Japan.
Antimicrob Agents Chemother ; 67(12): e0034623, 2023 12 14.
Article em En | MEDLINE | ID: mdl-37971240
ABSTRACT
Achromobacter spp. and Burkholderia cepacia complex (Bcc) are rare but diverse opportunistic pathogens associated with serious infections, which are often multidrug resistant. This study compared the in vitro antibacterial activity of the siderophore antibiotic cefiderocol against Achromobacter spp. and Bcc isolates with that of other approved antibacterial drugs, including ceftazidime-avibactam, ciprofloxacin, colistin, imipenem-relebactam, and meropenem-vaborbactam. Isolates were collected in the SIDERO multinational surveillance program. Among 334 Achromobacter spp. isolates [76.6% from respiratory tract infections (RTIs)], cefiderocol had minimum inhibitory concentration (MIC)50/90 of 0.06/0.5 µg/mL overall and 0.5/4 µg/mL against 52 (15.6%) carbapenem-non-susceptible (Carb-NS) isolates. Eleven (3.3%) Achromobacter spp. isolates overall and 6 (11.5%) Carb-NS isolates were not susceptible to cefiderocol. Among 425 Bcc isolates (73.4% from RTIs), cefiderocol had MIC50/90 of ≤0.03/0.5 µg/mL overall and ≤0.03/1 µg/mL against 184 (43.3%) Carb-NS isolates. Twenty-two (5.2%) Bcc isolates overall and 13 (7.1%) Carb-NS isolates were not susceptible to cefiderocol. Cumulative MIC distributions showed cefiderocol to be the most active of the agents tested in vitro against both Achromobacter spp. and Bcc. In a neutropenic murine lung infection model and a humanized pharmacokinetic immunocompetent rat lung infection model, cefiderocol showed significant bactericidal activity against two meropenem-resistant Achromobacter xylosoxidans strains compared with untreated controls (P < 0.05) and vehicle-treated controls (P < 0.05), respectively. Meropenem, piperacillin-tazobactam, ceftazidime, and ciprofloxacin comparators showed no significant activity in these models. The results suggest that cefiderocol could be a possible treatment option for RTIs caused by Achromobacter spp. and Bcc.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Achromobacter / Complexo Burkholderia cepacia Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Infecções Respiratórias / Achromobacter / Complexo Burkholderia cepacia Idioma: En Ano de publicação: 2023 Tipo de documento: Article